Clinical Report: Retrospective Analysis of the FinHer Protocol in Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients
Overview
This study evaluates the efficacy of the FinHer protocol in neoadjuvant treatment for HER2-positive breast cancer, reporting a pathological complete response (pCR) rate of 30%. It highlights the association of estrogen and progesterone receptor positivity with lower pCR rates and the impact of disease stage on survival outcomes.
Background
The introduction of trastuzumab has significantly changed the management of HER2-positive breast cancer, particularly in neoadjuvant settings. However, data on shorter trastuzumab regimens, such as the FinHer protocol, remain limited, especially in resource-constrained environments. Understanding the effectiveness of these regimens is crucial for optimizing treatment strategies in diverse populations.
Data Highlights
Parameter
Value
pCR Rate
30%
Stage III Disease
76 patients
Oligometastatic Disease
24 patients
ER/PR Positivity Impact on pCR
p = 0.002
HER2-Enriched vs Luminal B pCR Rates
47% vs 21.2% (p = 0.008)
DFS Hazard Ratio (Stage III vs Oligometastatic)
0.40 (p = 0.005)
OS Hazard Ratio (Stage III vs Oligometastatic)
0.35 (p = 0.003)
Key Findings
The pCR rate following the FinHer protocol was 30% in the study population.
ER and PR positivity were significantly associated with decreased pCR rates (p = 0.002).
Patients with the HER2-enriched subtype had higher pCR rates compared to those with the luminal B HER2-positive subtype (47% vs 21.2%, p = 0.008).
Stage III disease was a significant predictor of both disease-free survival (DFS) and overall survival (OS) (p = 0.003 and p = 0.002, respectively).
Achievement of pCR correlated with a numerically lower risk of death and recurrence.
Stage III disease was independently associated with improved survival outcomes compared to oligometastatic disease.
Clinical Implications
The findings suggest that the FinHer protocol can be an effective neoadjuvant treatment option for HER2-positive breast cancer, particularly in resource-limited settings. Clinicians should consider the impact of hormone receptor status on treatment outcomes and the importance of disease stage in predicting survival.
Conclusion
The study underscores the potential of the FinHer protocol in achieving pCR in HER2-positive breast cancer, while highlighting the need for further research to optimize treatment strategies based on receptor status and disease stage.
